Annals of Disaster Medicine
| ISSN:1684-193X
|
Updated
Dec 18 , 2005 |
|
Contents:
Volume 4, Supplement 1; October, 2005 |
|
Carbon Monoxide Intoxication |
Chung-Yu Cheng Huang, MD; Tzong-Luen Wang, MD, PhD |
From the Department of Emergency Medicine (Cheng Huang CY, Wang TL), Shin-Kong Wu Ho-Su Memorial Hospital,
Taiwan
Correspondence to Dr. Tzong-Luen Wang, Department of Emergency Medicine, 95 Wen Chang Road, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan . E-mail M002183@ms.skh.org.tw
|
Abstract
|
|
|
There is sufficient evidence to suggest that significant numbers of our population are being poisoned by low concentrations of carbon monoxide (CO). In otherwise healthy people, occult indoor exposure may result in commonplace symptoms such as headache, dizziness, weakness, and difficulty in concentrating. In people with pre-existing disease, pollution alone may result in increased morbidity and mortality. Variable symptoms and signs make the poisoning difficult to detect and lead to serious outcomes. Multiple laboratory and image study can help us to detect and diagnose CO poisoning. Although the use of hyperbaric oxygen (HBO) therapy is still controversial after many well-designed studies, many authors recommend the HBO in specific group. The other treatments, such as glucagon or steroid warrant further investigation. ED physicians have to learn to early detect the poisoning and to lower the morbidities and mortalities by appropriate management.
Key words---Carbon monoxide Poisoning;
HBO; Resuscitation
|
|
Epidemiology
|
|
|
|
CO is a colorless, odorless, and tasteless gas produced primarily as a result of any carbonaceous fossil fuel. Poisoning of CO remains the leading cause of poisoning mortality in the United States.1 It accounts for an estimated 40000 annual ED visits and 5000-6000 accidental deaths, most of them were due to motor vehicle exhaust and house fire. About 30% of CO poisoning patients were unintentional.2 The death rate from unintentional CO poisoning has declined over the past 3 decades, attributed in large part to prevention of motor vehicles exhaust exposures by stricter emissions control and public education programs.3 However, unintentional CO poisoning from some sources
remained common. One of these is exposure to CO produced by portable electrical
generators, powered by fossil fuels such as gasoline or propane and typically operated when
normal electrical service is disrupted by a storm or in remote
locations.4 The US Consumer Product Safety Commission summarized the 180 unintentional consumer product-related, non-fire-related CO deaths in 1998 as being associated with indoor heating system (71%), stoves and other appliances (10%), charcoal grills (9%), camp stoves (6%), and water heater (4%).5
|
|
|
Pathophysiology |
|
|
CO binds to hemoglobin with an affinity more than 220 to 240 times that of oxygen, replaces oxyhemoglobin by Hb-CO, and produces a relative anemia.6 It also causes a leftward shift in the oxygen-hemoglobin dissociation curve, decreases tissue oxygen delivery, and leads to tissue hypoxia. However, CO poisoning is much more complex than initially presumed and has mechanism of toxicity beyond the formation of Hb-CO. Some studies revealed that clinical morbidity and mortality due to CO poisoning independent of Hb-CO level or hypoxia. The current understanding of the pathophysiology of CO poisoning relates its clinical effect to the combination of direct CO toxicity and Hb-CO induced tissue hypoxia.7,8 CO may bind to many heme-containing proteins other than hemoglobin, like myoglobin,
cytochromes, and guanyly cyclase and would induced specific toxicity. Myocardial ischemia
or arrhythmia would be developed when CO binding to myoglobin. Rhabdomyolysis may
coexist.9 Binding to cytochrome would lead to
generation of free radicals due to disrupt the oxidative metabolism via cytochrome oxidase. The inactivation of mitochondrial enzyme may also lead to oxygen radicals
formation.10 CO also stimulates guanylyl cyclase, which increases
cyclic guanosine monophosphate resulting in cerebral vasodilatation and leads to loss of
consciousness.11 The role of nitric oxide (NO) and other free radicals has been researched and mentioned
broadly in the setting of CO poisoning. Increased NO level was noted in patients who
suffered from CO poisoning with loss of consciousness in many studies. Syncope may be
related to NO-mediated cerebral vessel relaxation and dilatation. NO is a peripheral
vasodilator which may lead to systemic hypotension
and predispose to the severity of cerebral
lesion.12 The delayed neurologic syndrome
(DNS) is also related to NO via the oxidative damage and brain lipid peroxidation after CO
poisoning.
|
|
|
Clinical Presentations |
|
|
The clinical presentations of CO poisoning are
variable and non-specific, which would be easily confused with other disease. Initial symptoms
of CO poisoning include headache, dizziness,
confusion, fatigue, nausea, vomiting, difficulty
concentrating, loss of consciousness, and coma(Table
1).13 The severity of symptoms is propo-tional to the exposed amount. The brain and the heart are the most oxygen-dependent organs and the most vulnerable to CO toxicity. Early neurologic manifestations include dizziness and headache. Increasing exposure may produce disturbance of consciousness, confusion, syncope, seizure, acute stroke-like syndromes, and coma. Mechanisms of brain injury following CO poisoning include hypoxia, excitotoxicity, binding to intracellular proteins and disrupting cellular metabolism, interference of intracellular enzyme function including P450, lipid peroxidation leading to oxidative injury, deposition of peroxynitrate (which damages blood vessel endothelium), apoptosis or programmed cell death, cerebral edema leading to secondary vascular effects, lacticacidosis, and oxidative stress from intracellular iron deposition.10,11 Early cardiovascular effects of CO poisoning are manifested as a response to hypoxia.
More significant exposure results in hypotension, dysrhythmia, ischemia, infarction, and in extreme
cases, cardiac arrest. Early deaths after CO exposure may be due to cardiac dysrhythmia.
CO poisoning also exacerbates underlying cardiovascular disorders. In patients with
undiagnosed underlying coronary artery disease, CO
exposure may act as a stress test similar to anemia. Even in healthy volunteers, CO
exposure has been found to result in non-specific
ECG changes.14 Myocardial infarction has been
reported in CO poisoning in the absence of underlying coronary artery
disease.15 QT dispersion (QTd) of the ECG, which was defined
as the difference between the greatest and the
least QT intervals in any of the 12 leads, is an
indirect measure of heterogeneity of ventricular repolarization, which may contribute to
ventricular arrhythmias. Gurkan et al documented that
QT dispersion increased in patients with CO poisoning in a 16 intoxicated patients series.
Increased QTd in the absence of QT interval prolongation may have a lowered
arrhythmogenic potential of CO poisoning.16 CO poisoning also may result in rhabdomyolysis and acute renal failure,
potentially as a direct toxic effect of CO on skeletal
muscle. Cutaneous blister and non-cardiogenic pulmonary edema have been reported in
patients with severe CO poisoning.
CO binds more tightly to fetal hemoglobin than adult one, making infants particularly
vulnerable to the toxicity. Symptoms in pediatric patients are often non-specific, such as
nausea and vomiting. Misdiagnosis of having viral
infection is not uncommon in CO
poisoning.17 CO exposure in pregnancy is an uncommon
event, but failing to recognize maternal CO intoxication can have a detrimental effect on the
fetus. CO crosses the placenta readily. Animal studies have shown that, with maternal CO
exposure, fetal Hb-CO levels reach a higher peak and eliminate more slowly than maternal
Hb-CO. Adverse outcomes, such as malformations, stillbirth and neurologic
disability, are related to more severe maternal
exposure.18 However, the level of maternal CO
haemoglobin is a poor indicator of fetal toxicity.
Despite maternal wellbeing, fetal morbidity or mortality can still occur. Postpartum hemorrhage
is a serious and potentially catastrophic obstetric complication. There was no previously
reported case of postpartum hemorrhage caused by acute CO poisoning. Patrick et al reported a 41-year-old woman presented with postpartum hemorrhage and altered mental status with
elevated serum Hb-CO level.19 In patients with acute poisoning, 30% or more may experience delayed onset of
neuropsychiatric symptoms (DNS).20 Symptoms
include cognitive and personality changes, dementia, psychosis, parkinsonism, amnesia,
depression, ataxia, hallucination, mutism, cortical blindness, and incontinence. Parkinsonism
is also one of the features of delayed CO encephalopathy, and has been reported to
occur in 9.5% of CO poisoning
patients.21 There is also good evidence that apparently minor
low level acute and chronic exposure causes varying degrees of neuropsychological
impairment.22 In general, patients who present
with a more symptomatic initial clinical picture are the most likely to develop persistent
sequelae or DNS. DNS occurs most frequently in patients who present unconsciousness, older
patients and patients with a prolonged exposure. Chronic, low-level CO exposure, such as may be seen in a workplace, also has been
linked to various symptoms, such as dizziness, headache, anorexia, apathy, insomnia, and
perhaps personality change. Chronic exposure may accelerate atherosclerosis. Polycythemia and
cardiomegaly have been reported in chronic exposure patients due to chronic
hypoxia.23
|
|
Table 1 . Common symptoms caused by carbon monoxide poisoning |
|
|
|
|
Diagnosis |
|
A high index of suspicion is essential to make the diagnosis of occult CO poisoning. In prospective observational studies, patients presenting to the ED with winter flu-like syndrome may have Hb-CO levels ranging from 3% to 24%.24 Histological factors that are important to elicit include the use of gas stoves for heat
and cohabitants with similar symptoms. In addition, patients whose symptoms are
associated with particular environments (i.e, workplace), activities (i.e, boating), or use of
appliances (i.e, stove, fireplace) may suffer from
CO exposure.25 Pulse oximetry may be falsely elevated in the setting of significant CO poisoning because
Hb-CO is difficult to distinguish from oxyhemoglobin by wavelength. The pulse oximetry
gap, defined as the difference between the measured pulse oximetry by finger probe and the
true pulse oximetry obtained spectro-phtometrically via co-oximeter, has been found
to approximate the Hb-CO level. As the Hb-CO level elevates, the degree of pulse
oximetry overestimation increases.26,27 Serum Hb-CO level should be obtained form patients suspected of CO exposure.
Endogenous production of CO occurs during heme catabolism by heme oxygenase but should
not produce Hb-CO level greater than 1%. The Hb-CO level may increase to 3~4% in
hemolytic anemia or sever sepsis.28 Whereas the
Hb-CO level of smokers may reach 10%. Low Hb-CO level often correlated with mild
symptoms, such as dizziness, headache and nausea. The level greater than 60~70% may
rapidly fatal. Several studies revealed a wide overlap between serum Hb-CO level and
clinical symptoms underscores the difficulty in
using level alone to determine the severity of exposure. So the clinical treatment strategies
cannot solely based on the Hb-CO
level.29 The severity of clinical symptoms is related not only
to the environmental CO concentration, but also to the duration of exposure. Sometimes,
because Hb-CO level declines with time and with oxygen therapy, an initial Hb-CO level may not
reflect accurately the magnitude of a patient's
exposure if it is drawn at a time that is remote from the exposure of after oxygen therapy has
been instituted. In some settings, exhaled CO levels measured by using a Breathalyzer-type
device can help to confirm the diagnosis, whether in the pre-hospital or ED
settings.30 Blood Hb-CO concentrations are described in reviews and textbooks, to exhibit a single exponential (i.e., linear on a semilogarithmic scale) decrease during the elimination process. However, a few reports have described a biphasic decrease in Hb-CO concentrations with a shorter half-life during the early phase of elimination after a short exposure to CO.31 Takeshi et al have shown in a preliminary report that blood Hb-CO shows a biphasic
decrease after short-term (3–8 minutes) exposure,
which was compatible with a two-compartment model and that the biphasic nature of the
elimination curve was not altered by various factors
that might affect the half-life of blood Hb-CO such as peak Hb-CO level, mode of exposure
to CO, or concentration of oxygen used during the CO elimination
phase.32 Routine blood gas analyzers without co-oximeters calculate rather
than measure oxyhemoglobin saturation and do not recognized the contribution of abnormal
hemoglobins. Arterial sampling is not necessary because prospective comparison of arterial and
venous Hb-CO levels in poisoning patients has shown a high degree of
correlation.33
Other diagnostic testing in the CO poisoning patient depends on the clinical scenario
and may include blood gas monitoring, electrolytes, cardiac markers, BUN and
creatinine, CPK, chest radiograph, ECG, neuropsychometric testing, and neuroimaging
studies. CXR may reveal non-cardiogenic pulmonary edema. ECG may show non-specific dysrhythmia or myocardial injury change.
Cardiac markers and CPK may be elevated. In different studies, performed on animal models,
changes in glucose and lactate levels correlate well with the extent and outcome of CO
poisoning, but such a correlation has not been shown in
humans.34 S100B, a structural protein of astroglial cells, has been shown to be a possible marker of CO poisoning in human. Miran Brvar et al demonstrate that acute carbon monoxide poisoning is associated with elevated S100B levels in a 42 rats model.35 CT of the brain in patients with severe CO exposure may show signs of cerebral infarction
secondary to hypoxia, ischemia and hypotention. A well reported finding is bilateral
globus pallidus low-density lesions due to local low blood flow, metabolic acidosis and
hypotension. Globus pallidus lesions may be delayed several days after initial presentation
and may resolve with time. Concomitant white matter lesions also may be seen. MRI in
patients with CO exposure may show diffuse, symmetric white matter lesions, predominantly
in the periventricular areas. Single-photon CT, EEG and quantitative MRI have been studied
as adjuvant diagnostic test in CO poisoning patients but generally are not widely available in
th ED. SPECT in particular may correlate better than other neuroimaging findings with
the development of delayed neurologic
sequelae.36 |
|
|
Treatment |
|
Treatment of the CO poisoning patients should begin with oxygen supplement and aggressive supportive care, including airway management, blood pressure support and stabilization of cardiovascular status. High-flow oxygen therapy
shoud be administered immediately to treat hypoxia resulting from CO poisoning and to
accelerate elimination of CO from the body. HBOT is not universally available and is not
risk-free. HBOT may have a role in preventing adverse neurologic sequelae in CO poisoning.
HBOT consists of the delivery of 100% oxygen within a pressured chamber resulting in a
manifold increase in the dissolve oxygen in the body. HBOT at 3.0 ATA was found in a
porcine study to provide enough dissolved oxygen to supply the body's need in the near-absence
of hemoglobin. 37 The half-life of Hb-CO is 240 to 320 minutes at room air, 40 to 80 minutes at 100% oxygen, and about 20 minutes at 100% HBOT at 2.5 to 3.0 ATA. 38 HBOT has been shown in CO poisoning animals not only to reduce CO binding to
hemoglobin, but also to reduce CO binding to other heme-containing proteins, such as
cytochrome aa3. HBOT also alter neutrophil
adhesion to endothelium, decrease free
radical-mediated oxidative damage, reduce neurologic
deficit and reduced overall
mortality. 39 Several case series comment on the apparent efficacy of HBOT compared with NBO
in reducing adverse neurologic outcome. One series of patient treat with HBOT after
CO-induced cardiac arrest yield no survivors. Patients presenting with acidosis or hypoxia or
patients receiving HBOT more than 6 hours after exposure tend to show increased morbidity and
mortality. Even in this population, late HBOT may result in improved neurologic
function. 40 Another series of 31 patients treated with
HBOT and 79 treated with NBO showed a “ poor outcome” in 6 of 31(19.4%) HBOT
patients and 35 of 79 (44.3%) NBO
patients. 41 Six prospective, randomized controlled trials compared HBOT with NBO for CO poisoning.
4 of these studies showed a benefit of HBOT and 2 of these didn’t. The conclusions of these
studies are conflicting and highlight the controversy of the utility of HBOT. Therefore, no
widespread agreement exists regarding selection of patients for HBOT in the setting of CO
poisoning, and a reliable method to identify patients at high risk for neurologic sequelae is not
available. Broad criteria for recommending HBOT for CO poisoning have included any
history of loss of consciousness, neurologic symptoms, cardiovascular dysfunction,
metabolic acidosis, abnormalities on neuropsychometric testing, pregnancy with
elevated Hb-CO ( >15~20%) level, persistent symptoms despite NBO, and significant high
Hb-CO level (>25%). 42,43Although the efficacy of one HBOT treatment protocol over another has not been
determined, one session of HBOT at 2.5 to 3.0 ATA is recommended initially, with further
sessions considered if symptoms persist. Patients not meeting criteria for HBOT should
receive 6 to 12 hours of 100% oxygen delivered by tight-fitting
facemask. 44 Infants and children receive the same HBOT protocols as adult.
Many authors recommend HBOT for pregnant patients due to the potential benefit to the fetus
and mother despite the safety of HBOT in pregnancy have been questioned. A maternal
Hb-CO level greater than 15% to 20%, evidence of fetal distress, and other criteria for HBOT in
CO poisoning often are cited as indications for HBOT in CO poisoning pregnant
patient. 45
The only absolute contraindication is untreated pneumothorax. Relative
contraindications include claustrophobia, otosclerosis or other scarring of middle ear, bowel
obstruction, significant COPD particular with bullae formation, and requirement of care
beyond what can be provided in a monoplace chamber. Most patients complian about painful
barotraumas affecting the ears and sinuses. Less common risk include seizure, pulmonary edema
and hemorrhage, oxygen toxicity, decompression sickness including pneumothorax and
nitrogen emboli. 44,46Normal physiologic processing of the small amount of CO naturally produced in the
body is regulated by at least 2 mechanisms that decrease the affinity of CO for the heme
molecule. One pathway involves the amino acid histidine, which, in proximity to the Hb-CO
complex, causes dissociation through steric hindrance. The second pathway involves
bisphosphoglycerate (BPG), an intermediate product in glycolysis and gluconeogenesis.
When BPG binds to heme, the affinity for CO is decreased, shifting the oxygen-dissociation
curve to the right. Glucagon contains a distal histidine and increases BPG levels by 2
enzymatic pathways. Treatment of CO poisoning with glucagon is a proposed novel therapeutic
approach to rapidly decrease CO blood levels by increasing steric hindrance of the heme-CO
association and by production of BPG, which decreases the affinity of heme for CO. However,
it didn’t revealed significant effect in glucagon group in one animal
model. 47Other treatments tried for CO poisoning in the past included hyperventilation,
hypothermia, osmotherapy, fluid restriction and glucorticoid, none of which have been found to
be effective.
|
|
|
Disposition |
|
|
Patients with mild exposure and mild symptoms can be treated in an ambulatory setting with high-flow oxygen. Neverthless, patients with moderate to severe poisoning should be considered to be admitted. 48 Mild poisong is defined by some authors as a Hb-CO level less than 25% and mild gastrointestinal symptoms and mild neurologic symptoms. Before discharging a patient from the ED, the source of CO poisoning may require investigation. Admission should be considered for patients with symptoms of moderate to severe CO poisoning, such as altered mental status or persistent neurologic or cardiovascular dysfunction. The companied comorbidities, such as cardiac ischemia, burns, or hemodynamic instability should received specialized care. Besides, not all facilities have the capability to provide the specialized care in addition to HBOT, adequate transfer is also mandatory. |
|
|
Summary |
|
|
CO is an insidious poison with a lot of exposure sources. CO poisoning presents with variable signs and symptoms and may mimic some non-specific viral infection. The clinical syndromes are often overlooked because of a range of presentations, obscure symptoms, and a lack of awareness of the problem. Failed to diagnose CO poisoning may result in significant morbidity and mortality. In the ED, a high index of suspicion must be maintained for possible CO poisoning.
ED management of CO poisoning include aggressive supportive care and oxygen
supplement. HBOT accelerate the dissociation of CO from hemoglobin and may prevent DNS.
Although the indications for HBOT still was controversial, the general indications which was
accepted by majority of authors include severe
neurologic or cardiovascular signs, high serum Hb-CO level (non-pregnancy with Hb-CO
level >25% or pregnant patients > 15 to 20%), metabolic acidosis, or persistent symptoms and signs despite 100% oxygen supplement. There was still no ideal HBOT protocol in nowadays. The emergency physicians have to confront and identify the insidious poison, and learn to make a suitable decision and disposition, even to transfer to hospitals with hyperbaric facilities. |
|
References |
|
|
|
1. |
Tomaszewski C. Carbon monoxide. In: Goldfrank LR, Flomenbaum NE, Lewin
NA, Howland MA, Hoffman RS, Nelson LS, editors. Goldfrank's toxicologic
emergencies. 7th edition. New York: McGraw-Hill; 2002. |
2. |
Hampson NB. Emergency department visits for carbon monoxide poisoning in the Pacific Northwest. J Emerg Med 1998;16:695-8. |
3. |
Mott JA, Wolfe MI, Alverson CJ, et al. National vehicle emissions policies and practices and declining U.S. carbon monoxide-related mortality. JAMA 2002;288:988-95. |
4. |
Michael Ghim, MD, and Harry W. Severance, MD. Ice Storm-related Carbon
Monoxide Poisonings in North Carolina: A Reminder, 2004 Southern Medical
Association, 1060-5. |
5. |
Mah JC. Non-fire carbon monoxide deaths and injuries associated with the use of
consumer produces: annual estimates. Bethesda, MD: US Consumer Product
Safety Commission. 2003. |
6. |
Haldane J. Medicolegal contributions of historical interest: the action of carbonic oxide on man. Forensic Sci 1972;1:
451-83. |
7. |
Goldbaum LR, Orellano T, dergal E. Mechanism of the toxic action of carbon
monoxide. Ann Clin Lab Sci 1976;6: 372-6. |
8. |
Ramirez RG, Albert SN, Agostin JC, Basu AP, Goldbaum LR. Lack of toxicity of transfused caarboxyhemoglobin. Surg Forum 1974;25:165-8. |
|
9. |
Richardson RS, Noyszewski EA, Saltin B, Gonzalez-Alonso J. Effect of mild carboxyhemoglobin on exercising skeletal muscle: intravascular and intrcellular evidence. Am J Physiol 2002;283: R1131-9. |
|
10.. |
Hardy KR, Thom SR. Pathophysiology and treatment of carbon monoxide poisoning. J Toxicol Clin Toxicol 1994;32:613-29. |
|
11. |
Barinaga M. Carbon monoxide: killer to brain messenger in one step. Science 1993;259:309. |
|
12. |
R Lynch,G Laden,P Grout. Carbon monoxide poisoning:correlation of neurological findings between accident and emergency departments and a hyperbaric unit. Emerg Med J 2001;18:95–8. |
|
13. |
Weaver LK. Carbon monoxide poisoning. Crit Care Clin 1999;15:297–317. |
|
14. |
Stewart RD, Peterson JE, Fisher TN, Hosko MJ, Baretta ED, Dodd HC. Experimental human exposure to high concentrations of carbon monoxide. Arch Environ Health 1973;26:1-7. |
|
15. |
Marius-Nunez AL. Myocardial infarction with normal coronary arteries after acute exposure to carbon monoxide. Chest 1990;97:491-4. |
|
16. |
GurkanY, Canatay H, Toprak A, Ural E and Toker K. Carbon monoxide poisoningaa cause of increased QTdispersion. Acta
Anaesthesiol Scand 2002; 46:180–3. |
17. |
Crocker PJ, Walker JS. Pediatric carbon monoxide toxicity. J Emerg Med 1985;3:443-8. |
18. |
Norma CA, Halton DM. Is carbon monoxide a workplace teratogen. Ann Occup Hyg 1990;34:335-47. |
19. |
Patrick S. Ramsey, Lane M. Meyer, Kirk D. Ramin, and Robert H. Heise. Delayed postpartum hemorrhage: A rare presentation of carbon monoxide poisoning. Am J Obs-Gyn 2001:243-4. |
20. |
Ernst A, Zibrak JD. Carbon monoxide poisoning. N Engl J Med 1998;339:1603–8. |
21. |
Choi IS. Parkinsonism after carbon monoxide poisoning Eur Neurol 2002;48:30-3. |
22. |
Amitai Y, Zlotogorski, Z, Golan-Katzav V, et al. Arch Neurol 1998;55:845–8. |
23. |
Erdogan MS, Islam SS, Chaudhari A. Occupational Carbon Monoxide Poisoning Among West Virginia Workers' Compensation Claims. JOEM 2004;46:577-83. |
24. |
Dolan MC, Haltom TL, Barrows GH, Short CS, Ferriell KM. Carboxyhemoglobin levels in patients with flu-like symptoms. Ann Emerg Med 1987;16:782-6. |
25. |
Heckerling PS, Leikin JB, Terzian CG, MaturenA. Occult carbon monoxide poisoning in patients with neurologic illness. J Toxicol Clin Toxicol 1990;28:29-44. |
26. |
Bozeman WP, Myers RA, Barish RA. Confirmation of the pulse oximetry gas in carbon monoxide poisoning. Ann Emerg Med 1997;20:608-11. |
27. |
Buckley RG, Aks SE, Eshom JL. The pulse oximetry gap in carbon monoxide intoxication. Ann Emerg Med
1994;24:252-5. |
28. |
Zegdi R, PerrinD, Burdin M, Boiteau R, Tenaillon A. Increased endogenous carbon monoxide production on severe sepsis. Intensive Care Med 2002;28:793-6. |
29. |
Norkool DM, Kirkpatrick JN. Treatment of acute carbon monoxide poisoning with hyperbaric oxygen: a review of 115 cases. Ann Emerg Med 1984;1:245-8. |
30. |
Kurt TL, Anderson RJ, Reed WG. Rapid estimation of carboxyhemoglobin by breath sampling in an emergency setting. Vet Hum Toxicol 1990;32:227-9. |
31. |
Godin G, Shephard RJ. On, the course of carbon monoxide uptake and release. Respiration. 1972;29:317–27. |
32. |
Shimazu T, Ikeuchi H, Sugimoto H, Goodwi CW. Half-life of blood carboxyhemoglobin after short-term and long-term exposure to carbon monoxide. J Trauma 2000;49:126-31. |
33. |
Touger M, Gallagher EJ, Tyrell J. Relationship between venous and arterial carboxyhemoglobin levels in patients with suspected carbon monoxide poisoning. Ann Emerg Med 1995;25:481-3. |
34. |
Benaissa ML, Megarbane B, Borron SW, et al. Is elevated plasma lactate a useful marker in the evaluation of pure carbon monoxide poisoning? Intensive Care Med 2003;29:1372–5. |
35. |
Brvar M, Mozina M, Osredkar J, Suput D. Prognostic value of S100B protein in carbon monoxide-poisoned rats. Crit Care Med 2004;32. |
36. |
Choi IS, Kim SK, Lee SS, Choi YC. Evaluation of outcome of delayed neurologic sequelae after carbon monoxide poisoning by technetium-99m hexamethylpropylene
amine oxime brain single photon emission computed
tomography.Eur Neurol 1995;35:137-42. |
37. |
Boerema I, Merne I, Mensch MH. Life without blood. Arch Chir Neerl 1959;11:70. |
38. |
Jay GD, McKindley DS. Alternations in pharmacokinetics of carboxyhemoglobin produced by oxygen under pressure. Undersea Hyperb Med 1997;24:165-73. |
39. |
Thom SR. Antagonism of carbon monoxide-mediated brain lipid peroxidation by hyperbaric oxygen. Toxicol Appl Pharmacol 1990;105:340-4. |
40. |
Piantadosi CA. Carbon monoxide poisoning. N Engl J Med 2002;347:1054-5. |
41. |
Hawkins M, Harrison J, Charters P. Severe carbon monoxide poisoning: outcome after hyperbaric oxygen therapy. Br J Anaesth. 2000;84:584-6. |
42. |
Thom SR, Hyperbaric-oxygen therapy for acute carbon monoxide poisoning. N Engl J Med 2002;347:1105-6. |
43. |
Myers RA, Snyder SK, Linberg S, Cowley RA. Value of hyperbaric oxygen in suspected carbon monoxide poisoning. JAMA 1981;246:2478-80. |
44. |
Finnerty JP. Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med 2003;348:557-60. |
45. |
Tomazeszewski CA, Thom SR. Use of hyperbaric oxygen in toxicology. Emerg Med Clin N Am 1994;12:437-59. |
46. |
Weaver LK, Hopkins RO, Elliott G. Carbon monoxide poisoning. N Engl J Med 1999;340:1290-2. |
47. |
O'Bryan EC, Veser FH, Veser B, Casey R, Charleston SC. Therapeutic Effects of glucagon on carbon monoxide Poisoning. Ann Emer Med 2004; 44:S92. |
48. |
Ernst A, Zibrak JD. Carbon monoxide poisoning. N Engl J Med 1998;339:1603-8. |
49. |
Haddad LM. Carbon monoxide poisoning: to transfer or not to transfer? Ann Emerg Med 1986;15:1375. |
|
|
|